# Immunotherapeutic Strategies for Prostate Cancer: A Comprehensive Review

## TL;DR

This paper reviews immunotherapy approaches for prostate cancer, including vaccines, checkpoint inhibitors, and CAR T-cell therapy, and discusses their potential and challenges.

## Contribution

The paper provides a comprehensive review of current and emerging immunotherapeutic strategies for prostate cancer, emphasizing personalized and combination therapies.

## Key findings

- Immunotherapies like dendritic cell vaccines and immune checkpoint inhibitors are being explored for prostate cancer.
- CAR T-cell therapy shows promise for advanced prostate cancer but is still in early development.
- Personalized and combination therapies are highlighted as future directions due to tumor heterogeneity.

## Abstract

Prostate cancer is the leading cause of cancer-related deaths worldwide and the second most common cancer in men. Immunological therapies include dendritic cell vaccines, immune checkpoint inhibitors, and adoptive cell therapy. This review explores the current landscape of prostate cancer. It analyzes treatment guidelines and examines immunotherapeutic strategies in use or research. Key areas include immune checkpoint inhibitors, adoptive cell therapy with CAR T-cell therapy, combination approaches, therapeutic synergies, and biomarkers that predict responses. Challenges and future directions in immunotherapy are also discussed.

Prostate cancer (PCa) is the leading cause of cancer-related deaths worldwide and the second most common cancer among men. Treatment options depend on factors like age, androgen sensitivity, PSA levels, Gleason score, TNM stage, and recurrence risk. Available treatments include hormonal therapy, radiation, surgery, and chemotherapy. Early immunological treatments were limited by poor lymphocyte infiltration and an immunosuppressive environment. Today, strategies such as dendritic cell vaccines, immune checkpoint inhibitors (ICIs), and adoptive cell therapy (ACT) are used. ACT, especially CAR T-cell strategies, aims to overcome traditional treatment limitations, particularly in advanced and metastatic castration-resistant prostate cancer (mCRPC), though it remains in early development. Personalized medicine uses molecular insights from the diseased tissue to tailor treatments. Variability in patient response, due to tumor heterogeneity and prior treatments, highlights the importance of personalized and combination therapies as future strategies for effective immunotherapy. This review explores the current landscape of PCa. We analyze treatment guidelines established by NCCN and EANM-ESTRO-ESUR-ISUP-SIOG. We comprehensively examine immunotherapeutic strategies currently available or under investigation for prostate cancer, with particular emphasis on ICIs, ACT with a focus on CAR T-cell therapy, combination approaches and therapeutic synergies, and predictive biomarkers of immunotherapy response. Additionally, we discuss the challenges and future directions in the implementation of immunotherapy for the management of prostate cancer.